Calliditas Therapeutics AB

PUBLISHED 8. January 2018 /

November 20, 2017.

Calliditas Therapeutics AB (formerly Pharmalink AB) announced today that the US Food & Drug Administration (FDA) has accepted its Phase 3 study design for its lead candidate Nefecon. A global Phase 3 program in IgA nephropathy has been initiated, and patient enrolment is expected to start in 2018.

https://www.calliditas.se/media/news-releases/surrogate-marker-and-design-calliditas-therapeutics-iga-nephropathy-phase-3-study-agreed-fda




Investinor klinkekuler